{
    "clinical_study": {
        "@rank": "8046", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A: BMS-823778 (2mg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment B: BMS-823778 (15mg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment C: Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to assess the effect of BMS-823778 on  reducing atherosclerotic\n      plaque inflammation"
        }, 
        "brief_title": "Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Atherosclerotic Cardiovascular Disease", 
        "condition_browse": {
            "mesh_term": [
                "Atherosclerosis", 
                "Cardiovascular Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented atherosclerotic cardiovascular disease or at high risk of cardiovascular\n             event\n\n          -  On stable statin dose\n\n          -  Clinically stable at time of screening and randomization\n\n        Exclusion Criteria:\n\n          -  Women of child bearing potential\n\n          -  Medical conditions that would impact the absorption of the study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666704", 
            "org_study_id": "MB121-010"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A: BMS-823778 (2mg)", 
                "description": "Capsules, Oral, 2mg, Once daily, 1 year", 
                "intervention_name": "BMS-823778", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B: BMS-823778 (15mg)", 
                "description": "Capsules, Oral, 15mg, Once daily, 1 year", 
                "intervention_name": "BMS-823778", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment C: Placebo", 
                "description": "Capsules, Oral, 0mg, Once daily, 1 year", 
                "intervention_name": "Placebo matching with BMS-823778", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 19, 2013", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "number_of_arms": "3", 
        "official_title": "A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Effects of BMS-823778 on Atherosclerotic Plaque Inflammation as Measured by Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET) in Patients With Atherosclerotic Cardiovascular Disease", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The effect of BMS-823778 versus placebo on carotids and/or ascending aortic will be measured by fluorodeoxyglucose (FDG) uptake in the index vessel as by positron emission tomography (PET) imaging", 
            "safety_issue": "No", 
            "time_frame": "Day 168"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666704"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Structural changes in the arterial wall (absolute, percent change, and both, from baseline in four indices): total vessel area, wall area, wall thickness, and wall area/total vessel area ratio (normalized wall index), based on the average of the right and left carotids, measured by Magnetic Resonance Imaging (MRI)", 
                "measure": "Structural changes in the arterial wall (absolute, percent change, and both, from baseline in four indices)", 
                "safety_issue": "No", 
                "time_frame": "Day 364"
            }, 
            {
                "measure": "Safety will be measured by adverse event, vital signs, electrocardiogram, physical examinations, clinical laboratory tests and Ferriman- Gallwey scores", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately up to 60 weeks"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}